Vasculitis & polymyalgia rheumatica
Real‐World Effectiveness and Safety of Secukinumab in Giant Cell Arteritis: An Italian Multicenter Cohort Study
Authors' conclusion
In this multicenter, real-world cohort of patients with GCA, including those with relapsing disease and previous biologic exposure, secukinumab was associated with high observed remission rates, progressive GC dose reduction, and increasing GC-free remission.
Study context
- Population
- Patients with giant cell arteritis (GCA) treated with secukinumab at 14 Italian centers (66.7% women; median age 74 years); 88.9% previously relapsed, 72.2% prior tocilizumab
- Participants
- 36 patients
- Outcome
- Clinical, complete and GC-free remission
- Follow-up
- 3, 6 and 12 months
Methodological detailsmulticenter, real-world, single-group
- Multicenter
- Real-world
- Single-group
Main finding
As reported in the abstract
Clinical remission at 3, 6 and 12 months
85.2%, 80.6%, and 83.3%
Complete remission at 3, 6 and 12 months
55.6%, 52.8%, and 63.3%
Glucocorticoid (GC)-free remission at 3, 6 and 12 months (increased progressively; P = 0.012)
14.8%, 27.8%, and 40.0%
Observational data: associations, not effects.
Further findings
Complete remission · 3, 6 and 12 months
- Complete remission at 3 months
- 55.6%
- Complete remission at 6 months
- 52.8%
- Complete remission at 12 months
- 63.3%
GC-free remission · 3, 6 and 12 months
- GC-free remission at 3 months
- 14.8%
- GC-free remission at 6 months
- 27.8%
- GC-free remission at 12 months
- 40.0%
- Progressive increase over time
- P = 0.012
Median daily GC dose · baseline to 12 months
- Median daily GC dose at baseline, mg (IQR 4.0-21.2)
- 8.7
- Median daily GC dose at 12 months, mg (IQR 0-5.0)
- 0
- Decrease from baseline to 12 months
- P < 0.001
- GCs discontinued, 12 of 28 patients
- 42.9%
Drug retention rate · 12 months
- 12-month retention rate
- 77.0%
Safety
Adverse events
- Adverse events, 20 of 36 patients
- 55.6%
Infections
- Infections, 18 of 36 patients
- 50.0%
- Infectious episodes
- 21
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →